{
    "clinical_study": {
        "@rank": "50541", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when\n      used with planar and SPECT imaging for the detection of breast cancer."
        }, 
        "brief_title": "Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients will be eligible for the study if they:\n\n          -  Are non-pregnant, non-lactating females 18 years of age or older(must agree to use an\n             appropriate and effective method of birth control during the study and for 2 weeks\n             after study)\n\n          -  Are being evaluated for a known or suspected breast tumor (must present with either a\n             mammographic abnormality 10mm or larger or a mammographically occult but palpable\n             abnormality of the breast)\n\n          -  Have been previously scheduled for biopsy or surgical excision of the known or\n             suspected tumor of the breast\n\n          -  Have signed an informed consent form\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Have a history or suspicion of significant allergic reaction or anaphylaxis to any of\n             the 111In-DAC components\n\n          -  Have a clinically unstable medical condition or opportunistic infection, a\n             life-threatening disease state, impaired renal or hepatic function or are\n             immunosuppressed\n\n          -  Are taking or have taken part in any investigational study within 30 days of start of\n             study\n\n          -  Have received an indium agent within 30 days of start of study\n\n          -  Are not able to remain immobile during scanning time\n\n          -  Have taken drugs that may damage the kidneys  within 2 weeks of start of study\n\n          -  Have abnormal laboratory test results: hemoglobin < 9.5 gms/dl, serum creatinine >\n             1.5 mg/100ml, alkaline phosphatase 2X the upper limit of normal\n\n          -  Have undergone an excisional and/or needle localization biopsy within 4 days prior to\n             start of study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 26, 2002", 
        "id_info": {
            "nct_id": "NCT00040430", 
            "org_study_id": "CP101"
        }, 
        "intervention": [
            {
                "intervention_name": "111In-DAC", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Diagnostic", 
                "intervention_type": "Procedure"
            }
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Roseville", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95661"
                    }, 
                    "name": "Sutter Roseville Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14214-3007"
                    }, 
                    "name": "University at Buffalo"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040430"
        }, 
        "source": "Copharos", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Copharos", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2003"
    }, 
    "geocoordinates": {
        "Sutter Roseville Medical Center": "38.752 -121.288", 
        "University at Buffalo": "42.886 -78.878"
    }
}